Heranba Industries Limited is a crop protection chemical manufacturer, exporter and marketing company based out of Vapi, Gujarat. They manufacture Intermediates, Technicals and Formulations. They are one of the leading domestic producers of synthetic pyrethroids like cypermethrin, alphacypermethrin, deltamethrin, permitherin, lambda cyhalothrin etc. Their Pesticides range includes insecticides, herbicides, fungicides and public health products for pest control.

Domestic Institutional sales of Technicals – Manufacturing and selling of Technicals in bulk to domestic companies;

Technicals Exports – Exports of Technicals in bulk to customers outside India;

Branded Formulations – Manufacturing and selling of Formulations under their own brands through their own distribution network in India;

Formulations Exports – Export of Formulations in bulk and customer specified packaging outside India.

Heranba Industries Ltd. IPO

Wants To Apply Online


Issue Details
Objects of the issue ·          To meet business working capital requirements.

·          General corporate purpose

·          To meet public expenses

Issue Size Total issue Size -Rs. 625 Cr.

Offer for Sale – Rs.  9,015,000 Shares

Fresh issue –  Rs. 60 Cr.

Face value  

Rs.10 Per Equity Share

Issue Price Rs. 626 – Rs. 627
Bid Lot 23 shares
Listing at  


Issue Opens: 23rd February, 2021 – 25th February, 2021
QIB 50% of Net Issue Offer
Retail 35% of Net Issue Offer
NIB 15% of Net Issue Offer



Check Heranba Industries Ltd. IPO Allotment Status

Heranba Industries Ltd. IPO allotment status would be available soon after the IPO closure date. Usually the allotment comes within a week from the closing date which in this IPO yet to be announced.

One can check the allotment on the given below link with PAN number or Application number or DP Client Id. All you need to do is to follow these steps:-

  1. To Heranba Industries Ltd. IPO IPO Allotment Status
  2. Go to Application Status
  3. Select IPO as Heranba Industries Ltd.
  4. Enter your PAN Number or Application Id or DP Client Id.


Heranba Industries Ltd. IPO

Application Form


Financial Performance:


Shareholding Pattern:

Shareholding Pattern Pre- Issue Post Issue
Promoters & Promoters Group 98.85% 74.15%
Public 1.15% 25.85%



  • Presence in a wide range of products across the entire value chain.
  • Strong product portfolio and wide distribution network.
  • Diversified and stable customer base
  • Product registrations in the domestic and international markets enabling global outreach.

Key Highlights:

  • Revenue increased by 26% from Rs 501.64 Crore  in H1FY20 to Rs.618.34 Crore in H1FY21 primarily led by increase in revenue from Domestic Institutional sales of Technicals and Branded Formulations by 31.00% and 71.89% respectively.
  • PAT Margins of the company improved to 10.72% in September quarter of FY21 from 7.51% in FY19.
  • 31% of Revenues of Heranba in FY20 comes from Exports

Risk Factors:

  • There are outstanding legal proceedings involving Company, Promoters and certain Directors which may adversely affect business.
  • In FY20 13.24% of revenue and 13.35% of Raw Materials of the company’s comes from China and any restriction or decline in exports to China could adversely affect company’s business
  • Raw materials constitute a significant percentage (70% as on September, 2020) of Company’s total expenses.


Heranba Industries Limited dominated the India pyrethroids market in 2019, accounting for a share of 19.5% of the total Indian pyrethroids production values. Global agrochemicals market is expected to grow at a CAGR of 4.11% during 2020-2025, reaching a value of US$ 73.39 Billion by 2025. Cypermethrin represented the most popular type in the global Pyrethroids market, accounting for 24.3% of total market in 2019. Cypermethrin used in long-lasting insecticidal nets is widely used to protect people from mosquitoes that carry malaria, dengue, and yellow fever diseases. Rallis India and Sumitomo Chemical India are the peers of the company trading at the price-to-earnings ratios of 24.71 and 47.49 respectively. Hiranba has highest  RoNW of 30.71 among its peers. At the higher end of the price band of Rs. 627, the stock will be available at a PE multiple of 20.64x on FY21E annualised Post issue EPS of Rs. 30.3. We would recommend Listing Gain to this IPO considering  valution and Risk Factors of the company.

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth
Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their
investment decision and must exercise their own judgment before making any investment decision.
For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth
Limited are registered/qualified as research analysts with SEBI in India. (SEBI Registration No.: INH100002300)
Disclosure Appendix
Analyst Certification (For Reports)
Manoj Vijay Shinde, Elite Wealth Limited, manojshinde@elitewealth.in
The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their
securities. I/We also certify that no part of my compensation was, is or will be, directly or inirectly, related to the specific recommendations or views expressed in this
report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.
As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that
the analyst covered in the report, that:
(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and
(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the
For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.
Research Excerpts
This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment
thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.
Company-Specific Disclosures
Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or emailing
research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research.
For important disclosures for these companies, please e-mail research@elitestock.com.
Options related research:
If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure
documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in
Other Disclosures
All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available
to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.
Ownership and material conflicts of interest Disclosure
Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of
coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth
Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, advisory board member or employee of any company
in the analyst’s area of coverage.
Country Specific Disclosures
India – For private circulation only, not for sale.
Legal Entities Disclosures
Mr. RavinderParkash Seth is the Managing Director of Elite Wealth Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course
Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and
Exchange Board of India. Telephone:011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in
EWL Advisory discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research
report, details of associates and such other information as is necessary to take an investment decision, including the following:
1. Reports
a) EWL Advisory or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;
(b) EWL Advisory or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of
the month immediately preceding the date of publication of the research report or date of the public appearance;
(c) EWL Advisory or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public
2. Compensation
(a) EWL Advisory or its associates have not received any compensation from the subject company in the past twelve months;
(b) EWL Advisory or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;
(c) EWL Advisory or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company
in the past twelve months;
(d) EWL Advisory or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage
services from the subject company in the past twelve months;
(e) EWL Advisory or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research
3 In respect of Public Appearances
(a) EWL Advisory or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided
by EWL Advisory
Provided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of
clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or
brokerage services transactions of the subject company.
(4) EWL Advisory or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL Advisory has never been engaged in market making activity for the subject company;
(6) EWL Advisory shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations.